365 related articles for article (PubMed ID: 30036516)
21. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats.
Bushinsky DA; Parker WR; Asplin JR
Kidney Int; 2000 Feb; 57(2):550-60. PubMed ID: 10652032
[TBL] [Abstract][Full Text] [Related]
22. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial.
Soygür T; Akbay A; Küpeli S
J Endourol; 2002 Apr; 16(3):149-52. PubMed ID: 12028622
[TBL] [Abstract][Full Text] [Related]
23. Citrate therapy for calcium phosphate stones.
Rimer JD; Sakhaee K; Maalouf NM
Curr Opin Nephrol Hypertens; 2019 Mar; 28(2):130-139. PubMed ID: 30531474
[TBL] [Abstract][Full Text] [Related]
24. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
[TBL] [Abstract][Full Text] [Related]
25. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.
Cheungpasitporn W; Erickson SB; Rule AD; Enders F; Lieske JC
J Urol; 2016 May; 195(5):1476-1481. PubMed ID: 26598423
[TBL] [Abstract][Full Text] [Related]
26. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
[TBL] [Abstract][Full Text] [Related]
27. Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference?
Tefekli A; Esen T; Ziylan O; Erol B; Armagan A; Ander H; Akinci M
Urol Int; 2003; 70(4):273-7. PubMed ID: 12740490
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of distal renal tubular acidosis in patients with calcium phosphate stones.
Guimerà J; Martínez A; Tubau V; Sabate A; Bauza JL; Rios A; Lopez M; Piza P; Grases F; Pieras E
World J Urol; 2020 Mar; 38(3):789-794. PubMed ID: 31079188
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of factors involved in calcium stone formation.
Abraham PA; Smith CL
Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
[TBL] [Abstract][Full Text] [Related]
30. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
[TBL] [Abstract][Full Text] [Related]
31. Effects of citrate on the different phases of calcium oxalate crystallization.
Tiselius HG; Berg C; Fornander AM; Nilsson MA
Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
[TBL] [Abstract][Full Text] [Related]
32. Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate.
Trinchieri A; Esposito N; Castelnuovo C
Arch Ital Urol Androl; 2009 Sep; 81(3):188-91. PubMed ID: 19911683
[TBL] [Abstract][Full Text] [Related]
33. Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis.
Tekin A; Tekgul S; Atsu N; Bakkaloglu M; Kendi S
J Urol; 2002 Dec; 168(6):2572-4. PubMed ID: 12441986
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate.
Jendle-Bengten C; Tiselius HG
Scand J Urol Nephrol; 2000 Feb; 34(1):36-41. PubMed ID: 10757268
[TBL] [Abstract][Full Text] [Related]
35. Urine calcium/citrate ratio in children with hypercalciuric stones.
Srivastava T; Winston MJ; Auron A; Alon US
Pediatr Res; 2009 Jul; 66(1):85-90. PubMed ID: 19287339
[TBL] [Abstract][Full Text] [Related]
36. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
Laube N; Jansen B; Hesse A
Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
[TBL] [Abstract][Full Text] [Related]
37. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
[TBL] [Abstract][Full Text] [Related]
38. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate.
Preminger GM; Sakhaee K; Pak CY
J Urol; 1988 Feb; 139(2):240-2. PubMed ID: 3339718
[TBL] [Abstract][Full Text] [Related]
39. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
[TBL] [Abstract][Full Text] [Related]
40. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
Pak CY; Sakhaee K; Fuller CJ
Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
